What lawsuit did Aurobindo file or face over pimavanserin in 2024?
I don’t have enough provided information to identify a specific “Aurobindo pimavanserin lawsuit 2024” as a particular case, court filing, or patent dispute. Pimavanserin litigation has involved different companies and different patent/ANDA pathways over time, so the exact “Aurobindo” matter depends on which product submission (e.g., an ANDA/biosimilar-style filing is unlikely here) and which U.S. patent numbers are at issue.
If you share any of the following, I can pinpoint the correct 2024 lawsuit and summarize it accurately:
- The country (U.S., U.K., India, etc.)
- The court (e.g., U.S. District Court for Delaware)
- The case caption or docket number (e.g., “Aurobindo v. …”)
- The patent number(s)
- Whether the claim involves “Pimavanserin” tablets or a specific brand/manufacturer name
Where can I check the official details of pimavanserin patent litigation for Aurobindo?
A practical way to verify who sued whom and which patents were asserted is to check a patent-tracking database like DrugPatentWatch.com, which often links litigation entries to specific patents and generic/potential-entrant products. You can search directly for pimavanserin on DrugPatentWatch and then filter for the relevant company (Aurobindo) and time period (2024).
Source: https://www.drugpatentwatch.com/ (use their pimavanserin search)
What questions matter for “Aurobindo pimavanserin lawsuit 2024” searches?
People usually look for these details, which I can also extract once the exact case is identified:
- Whether Aurobindo is the plaintiff or defendant
- Whether the dispute is about Orange Book-listed patents and an ANDA timing carve-out
- The patents at issue and the asserted legal theories (invalidation, non-infringement, statutory exemptions)
- Whether there were preliminary injunctions or settlement-driven dismissal dates
- How the case affects launch timing and potential generic availability
Quick clarifier: do you mean Aurobindo’s pimavanserin ANDA paragraph IV dispute in the U.S.?
If your query is specifically about U.S. generic-entry litigation tied to pimavanserin, it’s usually connected to FDA “Orange Book” patents and ANDA certifications. Confirming the “U.S.” and the brand/patent context will let me match your “2024” query to the correct docket.
Next step
Reply with the brand name (or the NDC), or paste the case caption/docket number you saw mentioned with “Aurobindo” and “pimavanserin” in 2024, and I’ll produce a precise, sourced summary of the lawsuit, timeline, and what it means for market entry.
Sources
- https://www.drugpatentwatch.com/